China Leads World in Next-Gen CAR-T Trials

Background and Context

A September 2026 Nature analysis showed China has overtaken the United States in next-generation CAR-T clinical trials, with over 300 registered studies—more than 40% of the global total. These next-gen therapies depart from conventional autologous CD19-targeted treatments for blood cancers, instead focusing on solid tumors, allogeneic “off-the-shelf” cells, and dual- or multi-targeting designs with safety switches. Approximately 60% of China’s trials target solid malignancies like liver, gastric, and pancreatic cancers, a share far above Western countries. This marks a shift from follower to leader in the global cell therapy landscape.

The surge reflects a strategic push to overcome first-generation CAR-T limitations: long manufacturing times, high costs, and poor solid-tumor efficacy due to antigen heterogeneity and immunosuppressive microenvironments. Leveraging a vast patient pool and improving clinical infrastructure, Chinese researchers have aggressively pursued novel constructs, reshaping the global pipeline.

Deep Analysis

China’s lead stems from converging technical, clinical, and regulatory factors. Technically, multi-targeted CAR designs combat antigen escape—a major relapse cause. Constructs targeting GPC3 and CD133 for liver cancer, or CLDN18.2 and PD-L1 for gastric cancer, exemplify this approach. Allogeneic universal CAR-T, using gene-edited donor cells with TCR and HLA knocked out to prevent GVHD and rejection, is another cornerstone. Companies like CARsgen, Legend Biotech, and Gracell Biotech aim to slash costs and turnaround times, with several candidates in pivotal trials.

Clinically, China’s large patient population and streamlined ethical reviews enable rapid enrollment. Hospital-based research capabilities have matured, creating an efficient target-to-validation continuum. The NMPA prioritizes cell therapy, allowing investigator-initiated trial data to support drug applications, bridging early research and commercial development. This bold exploration and supportive oversight foster a fertile innovation ecosystem.

Industry Impact

China’s trial leadership reshapes global dynamics. Multinationals like Novartis and Gilead increasingly license or co-develop Chinese next-gen CAR-T assets. Legend Biotech’s cilta-cel, partnered with Johnson & Johnson, is US-approved for multiple myeloma. Early-stage solid-tumor programs attract similar deals, creating a “China R&D, global development” model that provides Chinese biotechs upfront and milestone payments while leveraging global infrastructure.

Domestically, the boom risks overconcentration. Pipelines cluster around targets like CLDN18.2, GPC3, and mesothelin, with dozens of competing programs, potentially triggering price wars. Even if allogeneic platforms cut costs to one-tenth of autologous therapies, high absolute prices limit access without robust insurance or innovative payment models. As Chinese data accumulate, international regulators raise the bar for quality and long-term safety, demanding rigorous standards for global approval.

Outlook

Sustaining China’s lead hinges on several variables. Solid-tumor efficacy must be proven in randomized pivotal trials; most programs are early-phase with immature response and survival data. Allogeneic CAR-T durability remains a challenge, as donor cells persist shorter than autologous cells, requiring genetic tweaks or combination therapies to extend effect.

Regulatory tightening is likely as products proliferate, potentially squeezing smaller players. AI integration offers a new frontier—predicting targets, optimizing CAR design, and refining manufacturing—where China’s AI strengths could synergize. Payment innovation, such as outcomes-based reimbursement, is essential for real-world access. China’s trial leadership provides invaluable data, but becoming an industry powerhouse demands breakthroughs in original science, manufacturing, and commercial ecosystems.